Effect of platelets on the course of rheumatoid arthritis and cardiovascular risk


DOI: https://dx.doi.org/10.18565/therapy.2021.10.78-88

Mazurov V.I., Melnikov Е.S., Bashkinov R.A.

1) I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg; 2) Clinical Rheumatology Hospital No. 25, Saint Petersburg
Abstract. The prevalence of rheumatoid arthritis (RA) is estimated at 0,46% of the world population. In addition to the musculoskeletal system, the disease may have various extra-articular manifestations, including cardiovascular pathology. According to the literature, cardiovascular pathology is the main cause of death among patients with RA, reaching 39,6%. Apart from traditional risk factors of cardiovascular diseases (CVD), chronic systemic inflammation, characteristic for RA, is an independent predictor of cardiovascular pathology. This fact is reflected in modern scales of cardiovascular risk (CVR) calculation, which include the presence of systemic inflammation (including in RA) to avoid underestimating their impact on cardiovascular risks. The prevalence of elevated blood platelet levels in patients with RA is unknown. The role of thrombocytosis in the course of RA and its contribution to the formation of CVD and increased risk of CVR remains incompletely understood. This review presents data from the international literature, which studied the impact of platelets and platelet elevation in patients with RA on the course of the inflammatory process and the impact on cardiovascular organs.
Keywords: thrombocytosis, rheumatoid arthritis, cardiovascular complications, cardiovascular disease
Read entire article

Literature


  1. Мазуров В.И., Гайдукова И.З., Беляева И.Б. Клиническая ревматология. 3-е издание, переработанное и дополненное. Руководство для врачей. Под ред. В.И. Мазурова. М.: Е-ното. 2021; 696 с. [Mazurov V.I., Gaidukova I.Z., Belyaeva I.B. Clinical rheumatology. 3rd edition, revised and enlarged. A guide for doctors. Moscow: E-noto. 2021; 696 pp. (In Russ.)]. ISBN: 978-5-906023-26-1.

  2. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016; 388(10055): 2023–38. doi: 10.1016/S0140-6736(16)30173-8.

  3. Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018; 1: 32–39. [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2018; 1: 32–39 (In Russ.)]. https://dx.doi.org/10.18786/2072-0505-2018-46-1-32-39.

  4. Almutairi K., Nossent J., Preen D. et al. 749. The global prevalence of Rheumatoid Arthritis: A meta-analysis. Int J Epidemiol. 2021; 50(1): September dyab168.034. doi: 10.1093/ije/dyab168.034.

  5. Sokka T., Abelson B., Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008; 26(5 Suppl 51): S35–S61.

  6. Avina-Zubieta J.A., Thomas J., Sadatsafavi M. et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012; 71(9): 1524–29. doi: 10.1136/annrheumdis-2011-200726.

  7. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M. et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59(12): 1690–97. doi: 10.1002/art.24092.

  8. Hansildaar R., Vedder D., Baniaamam M. et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021; 3(1): e58–e70. doi: 10.1016/S2665-9913(20)30221-6.

  9. Arts E.E., Popa C., Den Broeder A.A. et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015; 74(4): 668–74. doi: 10.1136/annrheumdis-2013-204024.

  10. Crowson C.S., Matteson E.L., Roger V.L. et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012; 110(3): 420–24. doi: 10.1016/j.amjcard.2012.03.044.

  11. Hippisley-Cox J., Coupland C., Vinogradova Y. et al. Predicting cardiovascular risk in England and Wales: Prospective derivation and validation of QRISK2. BMJ. 2008; 336(7659): 1475–82. doi: 10.1136/bmj.39609.449676.25.

  12. Agca R., Heslinga S.C., Rollefstad S. et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017; 76(1): 17–28. doi: 10.1136/annrheumdis-2016-209775.

  13. Arts E.E., Popa C.D., Den Broeder A.A. et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016; 75(4): 674–80. doi: 10.1136/annrheumdis-2014-206879.

  14. Solomon D.H., Greenberg J., Curtis J.R. et al. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study [published correction appears in Arthritis Rheumatol. 2016; 68(2): 515]. Arthritis Rheumatol. 2015; 67(8): 1995–2003. doi: 10.1002/art.39195.

  15. Machlus K.R., Thon J.N., Italiano J.E. Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol. 2014; 165(2): 227–36. doi: 10.1111/bjh.12758.

  16. Garraud O., Cognasse F. Are Platelets Cells? And if yes, are they immune cells? Front Immunol. 2015; 6: 70. doi: 10.3389/fimmu.2015.00070.

  17. Amaya-Amaya J., Montoya-Sanchez L., Rojas-Villarraga A. Cardiovascular involvement in autoimmune diseases. Biomed Res Int. 2014; 2014: 367359. doi: 10.1155/2014/367359.

  18. Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015; 29(3): 153–62. doi: 10.1016/j.blre.2014.10.003.

  19. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115(12): 3339–47. doi: 10.1172/JCI26674.

  20. Harrison P., Goodall A.H. «Message in the platelet» – more than just vestigial mRNA! Platelets. 2008; 19(6): 395–404. doi: 10.1080/09537100801990582.

  21. Jackson M., Ahmad Y., Bruce I.N. et al. Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther. 2006; 8(3): R81. doi: 10.1186/ar1951.

  22. Weicht B., Maitz P., Kandler B. et al. Activated platelets positively regulate RANKL-mediated osteoclast differentiation. J Cell Biochem. 2007; 102(5): 1300–07. doi: 10.1002/jcb.21360.

  23. Gawaz M., Brand K., Dickfeld T. et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis. 2000; 148(1): 75–85. doi: 10.1016/s0021-9150(99)00241-5.

  24. Kaplanski G., Farnarier C., Kaplanski S. et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood. 1994; 84(12): 4242–48.

  25. Langer H.F., Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost. 2008; 99(3): 480–86. doi: 10.1160/TH07-11-0685.

  26. Elzey B.D., Sprague D.L., Ratliff T.L. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005; 238(1): 1–9. doi: 10.1016/j.cellimm.2005.12.005.

  27. Blair P., Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009; 23(4): 177–89. doi: 10.1016/j.blre.2009.04.001.

  28. Sprague D.L., Elzey B.D., Crist S.A. et al. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008; 111(10): 5028–36. doi: 10.1182/blood-2007-06-097410.

  29. Inwald D.P., McDowall A., Peters M.J. et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003; 92(9): 1041–48. doi: 10.1161/01.RES.0000070111.98158.6C.

  30. Rendu F., Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001; 12(5): 261–73. doi: 10.1080/09537100120068170.

  31. Łukasik Z.M., Makowski M., Makowska J.S. From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders. Rheumatol Int. 2018; 38(6): 959–74. doi: 10.1007/s00296-018-4001-9.

  32. Habets K.L., Huizinga T.W., Toes R.E. Platelets and autoimmunity. Eur J Clin Invest. 2013; 43(7): 746–57. doi: 10.1111/eci.12101.

  33. Kehrel B.E., Brodde M.F. State of the art in platelet function testing. Transfus Med Hemother. 2013; 40(2): 73–86. doi: 10.1159/000350469.

  34. Lood C., Tyden H., Gullstrand B. et al. Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One. 2014; 9(6): e99386. doi: 10.1371/journal.pone.0099386.

  35. Gasparyan A.Y., Stavropoulos-Kalinoglou A., Mikhailidis D.P. et al. Platelet function in rheumatoid arthritis: Arthritic and cardiovascular implications. Rheumatol Int. 2011; 31(2): 153–64. doi: 10.1007/s00296-010-1446-x.

  36. Arman M., Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost. 2015; 13(6): 893–908. doi: 10.1111/jth.12905.

  37. Habets K.L., Trouw L.A., Levarht E.W. et al. Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res Ther. 2015; 17(1): 209. doi: 10.1186/s13075-015-0665-7.

  38. Sokolove J., Brennan M.J., Sharpe O. et al. Brief report: Citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013; 65(7): 1719–24. doi: 10.1002/art.37961.

  39. Weyrich A.S., Zimmerman G.A. Platelets: Signaling cells in the immune continuum. Trends Immunol. 2004; 25(9): 489–95. doi: 10.1016/j.it.2004.07.003.

  40. Vazquez-Del Mercado M., Nunez-Atahualpa L., Figueroa-Sanchez M. et al. Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis patients without cardiovascular risk factors. Biomed Res Int. 2015; 2015: 342649. doi: 10.1155/2015/342649.

  41. Verschoor A., Langer H.F. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost. 2013; 110(5): 910–19. doi: 10.1160/TH13-02-0102.

  42. Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008; 67(5): 724–25. doi: 10.1136/ard.2007.073718.

  43. Barbarroja N., Perez-Sanchez C., Ruiz-Limon P. et al. Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014; 34(12): 2706–16. doi: 10.1161/ATVBAHA.114.304475.

  44. Boilard E., Nigrovic P.A., Larabee K. et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010; 327(5965): 580–83. doi: 10.1126/science.1181928.

  45. Kojima F., Naraba H., Sasaki Y. et al. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum. 2003; 48(10): 2819–28. doi: 10.1002/art.11261.

  46. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010; 233(1): 233–55. doi: 10.1111/j.0105-2896.2009.00859.x.

  47. Reich N., Beyer C., Gelse K. et al. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med. 2011; 15(4): 756–62. doi: 10.1111/j.1582-4934.2010.01051.x.

  48. Jungel A., Distler O., Schulze-Horsel U. et al. Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum. 2007; 56(11): 3564–74. doi: 10.1002/art.22980.

  49. Cloutier N., Tan S., Boudreau L.H. et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med. 2013; 5(2): 235–49. doi: 10.1002/emmm.201201846.

  50. Lundberg K., Nijenhuis S., Vossenaar E.R. et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther. 2005; 7(3): R458–R467. doi: 10.1186/ar1697.

  51. Burska A.N., Hunt L., Boissinot M. et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014; 2014: 492873. doi: 10.1155/2014/492873.

  52. Maugeri N., Rovere-Querini P., Manfredi A.A. Disruption of a regulatory network consisting of neutrophils and platelets fosters persisting inflammation in rheumatic diseases. Front Immunol. 2016; 7: 182. doi: 10.3389/fimmu.2016.00182.

  53. Khandpur R., Carmona-Rivera C., Vivekanandan-Giri A. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013; 5(178): 178ra40. doi: 10.1126/scitranslmed.3005580.

  54. Peerschke E.I., Yin W., Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010; 47(13): 2170–75. doi: 10.1016/j.molimm.2010.05.009.

  55. Gros A., Ollivier V., Ho-Tin-Noe B. Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol. 2015; 5: 678. doi: 10.3389/fimmu.2014.00678.

  56. Mauler M., Bode C., Duerschmied D. Platelet serotonin modulates immune functions. Hamostaseologie. 2016; 36(1): 11–16. doi: 10.5482/HAMO-14-11-0073.

  57. Palmer D.G., Hogg N., Revell P.A. Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involved by rheumatoid arthritis. A study with monoclonal antibodies. Pathology. 1986; 18(4): 431–37. doi: 10.3109/00313028609087564.

  58. Schmitt-Sody M., Metz P., Gottschalk O. et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets. 2007; 18(5): 365–72. doi: 10.1080/09537100701191315.

  59. Schmitt-Sody M., Metz P., Klose A. et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol. 2007; 36(4): 311–19. doi: 10.1080/03009740701218741.

  60. Waguri-Nagaya Y., Otsuka T., Sugimura I. et al. Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees. Rheumatol Int. 2000; 20(1): 13–19. doi: 10.1007/s002960000067.

  61. Avramakis G., Papadimitraki E., Papakonstandinou D. et al. Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets. 2007; 18(1): 16–23. doi: 10.1080/09537100600800412.

  62. Muscari A., De Pascalis S., Cenni A. et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost. 2008; 99(6): 1079–84. doi: 10.1160/TH07-12-0712.

  63. Colkesen Y., Acil T., Abayli B. et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis. 2008; 19(5): 411–14. doi: 10.1097/MBC.0b013e3283049697.

  64. Endler G., Klimesch A., Sunder-Plassmann H. et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002; 117(2): 399–404. doi: 10.1046/j.1365-2141.2002.03441.x.

  65. Martin J.F., Bath P.M., Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991; 338(8780): 1409–11. doi: 10.1016/0140-6736(91)92719-i.

  66. Bath P., Algert C., Chapman N., Neal B.; PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004; 35(3): 622–26. doi: 10.1161/01.STR.0000116105.26237.EC.

  67. Coban E., Adanir H. Platelet activation in patients with Familial Mediterranean Fever. Platelets. 2008; 19(6): 405–08. doi: 10.1080/09537100802187121.

  68. Bhatia G.S., Sosin M.D., Patel J.V. et al. Plasma indices of endothelial and platelet activation in Rheumatoid Disease: relationship to cardiovascular co-morbidity. Int J Cardiol. 2009; 134(1): 97–103. doi: 10.1016/j.ijcard.2008.01.038.

  69. Fink P.C., Piening U., Fricke P.M., Deicher H. Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum. 1979; 22(8): 896–903. doi: 10.1002/art.1780220814.

  70. Saeed S.A., Gilani A.H., Rasheed H. et al. Plasma from rheumatoid patients taking low dose methotrexate enhances platelet aggregation. Res Commun Mol Pathol Pharmacol. 2002; 111(1–4): 69–76.

  71. Knijff-Dutmer E.A., Kalsbeek-Batenburg E.M., Koerts J., van de Laar M.A. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002; 41(4): 458–61. doi: 10.1093/rheumatology/41.4.458.

  72. Alcalay M., Bontoux D., Peltier A. et al. C7 deficiency, abnormal platelet aggregation, and rheumatoid arthritis. Arthritis Rheum. 1981; 24(1): 102–03. doi: 10.1002/art.1780240118.

  73. Falus A., Meretey K., Bagdy D. et al. Beta-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation. Clin Exp Immunol. 1982; 47(1): 103–09.

  74. Riddle J.M., Bluhm G.B., Pitchford W.C. et al. A comparative study of platelet reactivity in arthritis. Ann N Y Acad Sci. 1981; 370: 22–29. doi: 10.1111/j.1749-6632.1981.tb29717.x.

  75. Colli S., Maderna P., Tremoli E. et al. Platelet function in rheumatoid arthritis. Scand J Rheumatol. 1982; 11(3): 139–43. doi: 10.3109/03009748209098179.

  76. Al-Ghamdi A., Attar S.M. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009; 29(3): 189–93. doi: 10.4103/0256-4947.51774.

  77. Ertenli I., Haznedaroglu I.C., Kiraz S. et al. Cytokines affecting megakaryocytopoiesis in rheumatoid arthritis with thrombocytosis. Rheumatol Int. 1996; 16(1): 5–8. doi: 10.1007/BF01419947.

  78. Ertenli I., Kiraz S., Oztürk M.A. et al. Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int. 2003; 23(2): 49–60. doi: 10.1007/s00296-003-0289-0.

  79. Kiraz S., Ertenli I., Ozturk M.A. et al. Bloodstream thrombopoietin in rheumatoid arthritis with thrombocytosis. Clin Rheumatol. 2002; 21(6): 453–56. doi: 10.1007/s100670200114.

  80. Hutchinson R.M., Davis P., Jayson M.I. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis. 1976; 35(2): 138–42. doi: 10.1136/ard.35.2.138.

  81. Ertenli I., Kiraz S., Arici M. et al. P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol. 1998; 25(6): 1054–58.

  82. Farr M., Scott D.L., Constable T.J. et al. Thrombocytosis of active rheumatoid disease. Ann Rheum Dis. 1983; 42(5): 545–49. doi: 10.1136/ard.42.5.545.

  83. Ehrenfeld M., Penchas S., Eliakim M. Thrombocytosis in rheumatoid arthritis. Recurrent arterial thromboembolism and death. Ann Rheum Dis. 1977; 36(6): 579–81. doi: 10.1136/ard.36.6.579.

  84. Pines A., Kaplinsky N., Olchovsky D. et al. Recurrent transient ischemic attacks associated with thrombocytosis in rheumatoid arthritis. Clin Rheumatol. 1982; 1(4): 291–93. doi: 10.1007/BF02032089.

  85. Casado Naranjo I., Martin Gonzalez R., Sancho Rieger J. et al. Transient ischaemic attacks associated with thrombocytosis in active rheumatoid arthritis. J Neurol Neurosurg Psychiatry. 1988; 51(12): 1599. doi: 10.1136/jnnp.51.12.1599.

  86. Milovanovic M., Nilsson E., Jaremo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta. 2004; 343(1–2): 237–40. doi: 10.1016/j.cccn.2003.12.030.

  87. Kacena M.A., Horowitz M.C. The role of megakaryocytes in skeletal homeostasis and rheumatoid arthritis. Curr Opin Rheumatol. 2006; 18(4): 405–10. doi: 10.1097/01.bor.0000231910.42666.31.

  88. Talukdar M., Barui G., Adhikari A. et al. A Study on association between common haematological parameters and disease activity in rheumatoid arthritis. J Clin Diagn Res. 2017; 11(1): EC01–EC04. doi: 10.7860/JCDR/2017/23524.9130.

  89. Yazici S., Yazici M., Erer B. et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010; 21(2): 122–25. doi: 10.3109/09537100903474373.

  90. Moghimi J., Ghahremanfard F., Salari M., Ghorbani R. Association between mean platelet volume and severity of rheumatoid arthritis. Pan Afr Med J. 2017; 27: 276. doi: 10.11604/pamj.2017.27.276.12228.

  91. Kisacik B., Tufan A., Kalyoncu U. et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75(3): 291–94. doi: 10.1016/j.jbspin.2007.06.016.

  92. Gasparyan A.Y., Sandoo A., Stavropoulos-Kalinoglou A., Kitas G.D. Mean platelet volume in patients with rheumatoid arthritis: The effect of anti-TNF-α therapy. Rheumatol Int. 2010; 30(8): 1125–29. doi: 10.1007/s00296-009-1345-1.

  93. Khaled S.A.A., NasrEldin E., Makarem Y.S., Mahmoud H.F.F. Value of platelet distribution width and mean platelet volume in Disease Activity Score of rheumatoid arthritis. J Inflamm Res. 2020; 13: 595–606. doi: 10.2147/JIR.S265811.


About the Autors

Vadim I. Mazurov, MD, professor, academician of RAS, Honored worker of science of Russian Federation, Director of the Research Institute of Rheumatology of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, head of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald, I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, head of autoimmune center of Clinical Rheumatology Hospital No. 25 (Saint Petersburg). Address: 191015, Saint Petersburg, 41 Kirochnaya Str. E-mail: maz.nwgmu@yandex.ru. ORCID: 0000-0002-0797-2051. SPIN-code: 6823-5482
Evgeny S. Melnikov, postgraduate student at the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald, I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, rheumatologist at Clinical Rheumatology Hospital No. 25 (Saint Petersburg). Address: 190068, Saint Petersburg, 30 Bolshaya Podyacheskaya Str. E-mail: melnikovzhenya@mail.ru. ORCID: 0000-0002-8521-6542
Roman Andreevich Bashkinov, postgraduate student at the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald, I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, rheumatologist at Clinical Rheumatology Hospital No. 25 (Saint Petersburg). Address: 190068, Saint Petersburg, 30 Bolshaya Podyacheskaya Str. E-mail: bashkinov-roman@mail.ru; ORCID: 0000-0001-9344-1304. SPIN-code: 5169-5066


Similar Articles

Back to Content

Бионика Медиа